- Home
- ZH vs CGEM Comparison
ZH vs CGEM Comparison
Compare ZH & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- CGEM
- Stock Information
- Founded
- ZH 2011
- CGEM 2016
- Country
- ZH China
- CGEM United States
- Employees
- ZH N/A
- CGEM N/A
- Industry
- ZH Business Services
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- CGEM Health Care
- Exchange
- ZH Nasdaq
- CGEM Nasdaq
- Market Cap
- ZH 397.3M
- CGEM 437.2M
- IPO Year
- ZH 2021
- CGEM 2021
- Fundamental
- Price
- ZH $3.69
- CGEM $11.71
- Analyst Decision
- ZH Strong Buy
- CGEM Strong Buy
- Analyst Count
- ZH 1
- CGEM 7
- Target Price
- ZH $4.70
- CGEM $27.14
- AVG Volume (30 Days)
- ZH 176.0K
- CGEM 1.2M
- Earning Date
- ZH 11-25-2025
- CGEM 11-06-2025
- Dividend Yield
- ZH N/A
- CGEM N/A
- EPS Growth
- ZH N/A
- CGEM N/A
- EPS
- ZH 0.17
- CGEM N/A
- Revenue
- ZH $416,437,241.00
- CGEM N/A
- Revenue This Year
- ZH N/A
- CGEM N/A
- Revenue Next Year
- ZH $6.47
- CGEM N/A
- P/E Ratio
- ZH $22.04
- CGEM N/A
- Revenue Growth
- ZH N/A
- CGEM N/A
- 52 Week Low
- ZH $3.19
- CGEM $5.68
- 52 Week High
- ZH $6.32
- CGEM $13.78
- Technical
- Relative Strength Index (RSI)
- ZH 28.64
- CGEM 68.82
- Support Level
- ZH $3.48
- CGEM $8.52
- Resistance Level
- ZH $4.14
- CGEM $13.33
- Average True Range (ATR)
- ZH 0.16
- CGEM 1.01
- MACD
- ZH -0.02
- CGEM 0.42
- Stochastic Oscillator
- ZH 24.70
- CGEM 76.36
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.